Search Result

Results for "

Vildagliptin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Cytochrome P450 (1) Dipeptidyl Peptidase (5) Ferroptosis (5) Isotope-Labeled Compounds (3)
By Research Areas:	Cancer (2) Metabolic Disease (9)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14291

*Vildagliptin* 4 Publications Verification LAF237; NVP-LAF 237	Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease Cancer
Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-14291B

(2R)-Vildagliptin (2R)-LAF237; (2R)-NVP-LAF 237	Others	Metabolic Disease
(2R)-Vildagliptin is the isomer of Vildagliptin (HY-14291), and can be used as an experimental control. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-14291R

Vildagliptin (Standard)	Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease
Vildagliptin (Standard) is the analytical standard of Vildagliptin. This product is intended for research and analytical applications. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-G0024A

Vildagliptin carboxylic acid metabolite TFA Vildagliptin carboxy acid metabolite TFA	Cytochrome P450	Metabolic Disease
Vildagliptin carboxylic acid metabolite (M20.7) TFA is a potent P450 enzyme activity inhibitor .

HY-14291S1

Vildagliptin-d7 LAF237-d₇; NVP-LAF 237-d₇	Isotope-Labeled Compounds Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease
Vildagliptin-d₇ is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

HY-14291S

Vildagliptin-d3 LAF237-d₃; NVP-LAF 237-d₃	Isotope-Labeled Compounds Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease
Vildagliptin-d₃ is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].

HY-14291A

Vildagliptin dihydrate LAF237 dihydrate; NVP-LAF 237 dihydrate	Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease Cancer
Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-14291S2

Vildagliptin-13C5,15N LAF237-¹³C₅,¹⁵N; NVP-LAF 237-¹³C₅,¹⁵N	Isotope-Labeled Compounds	Metabolic Disease
Vildagliptin- ¹³C₅, ¹⁵N (LAF237- ¹³C₅, ¹⁵N; NVP-LAF 237- ¹³C₅, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-139792

Besigliptin tosylate SHR117887	Others	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

Cat. No.	Product Name	Chemical Structure

HY-14291S1

Vildagliptin-d7
Vildagliptin-d₇ is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

HY-14291S

Vildagliptin-d3
Vildagliptin-d₃ is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].

HY-14291S2

Vildagliptin-13C5,15N
Vildagliptin- ¹³C₅, ¹⁵N (LAF237- ¹³C₅, ¹⁵N; NVP-LAF 237- ¹³C₅, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

Vildagliptin-13C5,15N

Vildagliptin- ¹³C₅, ¹⁵N (LAF237- ¹³C₅, ¹⁵N; NVP-LAF 237- ¹³C₅, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.